Skip to main content

Selpercatinib Side Effects

Medically reviewed by Last updated on Jul 23, 2023.

Applies to selpercatinib: oral capsule.

Serious side effects of Selpercatinib

Along with its needed effects, selpercatinib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking selpercatinib:

More common

Less common

Other side effects of Selpercatinib

Some side effects of selpercatinib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to selpercatinib: oral capsule.


Very common (10% or more): Leukocytes decreased (43%), platelets decreased (33%), hemorrhage (e.g., epistaxis, hematuria, hemoptysis, contusion, rectal hemorrhage, vaginal hemorrhage, ecchymosis, hematochezia, petechiae, traumatic hematoma, anal hemorrhage, blood blister, blood urine present, cerebral hemorrhage, GI hemorrhage, hemorrhage intracranial, spontaneous hematoma, abdominal wall hematoma, angina bullosa hemorrhagica, diverticulum intestinal hemorrhagic, eye hemorrhage, GI hemorrhage, gingival bleeding, hematemesis, hemorrhagic anemia, intraabdominal hemorrhage, lower GI hemorrhage, melena, mouth hemorrhage, occult blood positive, pelvic hematoma, periorbital hematoma, pharyngeal hemorrhage, pulmonary contusion, purpura, retroperitoneal hematoma, subarachnoid hemorrhage, subdural hemorrhage, upper GI hemorrhage, vessel puncture site hematoma) (15%)

Common (1% to 10%): Hemorrhagic events[Ref]


Common (1% to 10%): Hypersensitivity[Ref]


Very common (10% or more): Glucose increased (44%), albumin decreased (42%), calcium decreased (41%), alkaline phosphatase increased (36%), total cholesterol increased (31%), sodium decreased (27%), magnesium decreased (24%), bilirubin increased (23%), glucose decreased (22%)[Ref]


Very common (10% or more): Increased AST (51%), increased ALT (45%)[Ref]


Very common (10% or more): Cough (e.g., cough, productive cough) (18%), dyspnea (e.g., dyspnea, dyspnea exertional, dyspnea at rest) (16%)[Ref]


Very common (10% or more): Fatigue (e.g., fatigue, asthenia, malaise) (35%), edema (e.g., edema, edema peripheral, face edema, eye edema, eyelid edema, generalized edema, localized edema, lymph edema, scrotal edema, peripheral swelling, scrotal swelling, swelling, swelling face, eye swelling, peripheral swelling) (33%)

Frequency not reported: Impaired wound healing[Ref]


The most common adverse reactions, including laboratory abnormalities, (25% or greater) were increased aspartate aminotransferase (AST), increased alanine aminotransferase (ALT), increased glucose, decreased leukocytes, decreased albumin, decreased calcium, dry mouth, diarrhea, increased creatinine, increased alkaline phosphatase, hypertension, fatigue, edema, decreased platelets, increased total cholesterol, rash, decreased sodium, and constipation.[Ref]

Nervous system

Very common (10% or more): Headache (e.g., headache, sinus headache, tension headache) (23%)[Ref]


Very common (10% or more): Creatinine decreased (37%)[Ref]


Very common (10% or more): Hypertension (35%), QT prolongation (17%)[Ref]


Very common (10% or more): Rash (e.g., rash erythematous, rash macular, rash maculopapular, rash morbilliform, rash pruritic) (27%)[Ref]


Common (1% to 10%): Hypothyroidism[Ref]


Very common (10% or more): Dry mouth (39%), diarrhea (e.g., diarrhea, defecation urgency, frequent bowel movements, anal incontinence) (37%), constipation (25%), nausea (23%), abdominal pain (e.g., abdominal pain, abdominal pain upper, abdominal pain lower, abdominal discomfort, Gi pain) (23%), vomiting (15%)[Ref]


1. Product Information. Retevmo (selpercatinib). Lilly, Eli and Company. 2020.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.